1 - SYSTEMIC CORTICOSTEROIDS Flashcards
1
Q
The inactive form cortisone is converted to the active form cortisol (hydrocortisone) by 11 beta-hydroxysteroid dehydrogenase in the liver
A
True (both cortisone and cortisol/hydrocortisone are short acting corticosteroid)
2
Q
The addition of a 1,2 double bond to cortisol (hydrocortisone) results in prednisone with increased glucocorticoid activity and decreased rate of metabolic degradation
A
True (prednisone is an intermediate acting corticosteroid)
3
Q
Prednisolone is the active analog of prednisone (both intermediate acting corticosteroids)
A
True (prednisone is converted to prednisolone through 11-hydroxylation)
4
Q
Prednisone is converted to its active analog prednisolone through 11-hydroxylation
A
True (both are intermediate acting corticosteroid)
5
Q
Methylprednisolone is formed through the addition of a 6-methyl group to prednisolone (active analog of prednisone), which leads to slightly increased glucocorticoid activity
A
True (Methylprednisolone is an intermediate acting corticosteroid)
6
Q
Cortisone and cortisol (hydrocortisone) are short acting corticosteroids
A
True
7
Q
Prednisone, prednisolone (active analog of prednisone), Methylprednisolone and Triamcinolone are intermediate acting corticosteroids
A
True
8
Q
Dexamethasone and betamethasone are long acting corticosteroids
A
True
9
Q
The addition of fluorine to cortisol (hydrocortisone) leads to increased glucocorticoid but also significant mineralocorticoid activity and results in fludrocortisone
A
True
10
Q
By modifying fludrocortisone (high glucocorticoid and mineralocorticoid activity), 3 compounds (Triamcinolone, dexamethasone and betamethasone) with high glucocorticoid and low mineralocorticoid effects are formed
A
True (all 3 compounds are biologically active due to the 11-hydroxyl group and do not require 11 beta-hydroxysteroid dehydrogenase for conversion to active form)
11
Q
All corticosteroids have a hydroxyl group at the 17 position (17-hydroxycorticosteroids)
A
True
12
Q
The long acting corticosteroids (dexamethasone and betamethasone) have higher glucocorticoid potency than the shorter acting corticosteroids (cortisone and cortisol/hydrocortisone)
A
True (prednisone, prednisolone, methylprednisolone and Triamcinolone are intermediate acting corticosteroids)
13
Q
The shorter acting corticosteroids (cortisone and cortisol/hydrocortisone) have mineralocorticoid activity as compared to the longer acting corticosteroids (dexamethasone and betamethasone) which have little/no mineralocorticoid activity
A
True (there is an inverse correlation between the duration of action I.e. Potency and the relative mineralocorticoid effects)
14
Q
Exogenous corticosteroid are absorbed in the upper jejunum
A
True
15
Q
Food does not reduce the amount of prednisone absorbed
A
True (only delays absorption)
16
Q
Food delays the absorption of prednisone
A
True (but does not reduce the amount absorbed)
17
Q
80-90% of endogenous cortisol/hydrocortisone is bound to cortisol-binding globulin
A
True (the free fraction represents the active form)
18
Q
The free fraction of cortisol is the active form
A
True
19
Q
The primary endogenous carrier protein for cortisol is cortisol-binding globulin and it is a low capacity high affinity binding system
A
True (in contrast to albumin which is a high capacity but low affinity reserve)
20
Q
The binding of synthetic exogenous corticosteroids to plasma proteins (cortisol-binding globulin or albumin) is less than the avidity with which endogenous cortisol is bound, hence a greater free fraction of exogenous corticosteroid is available
A
True
21
Q
Prednisolone (active analog of prednisone) binds to plasma carrier proteins with greater affinity to other exogenous forms, with resultant potential for displacement of endogenous cortisol from the protein-binding sites
A
True
22
Q
Cortisol-binding globulin is decreased in hypothyroidism which may result in increased amount of the endogenous and synthetic corticosteroid free fraction
A
True
23
Q
Cortisol-binding globulin is decreased in liver disease which may result in increased amount of the endogenous and synthetic corticosteroid free fraction
A
True
24
Q
Cortisol-binding globulin is decreased in renal disease which may result in increased amount of the endogenous and synthetic corticosteroid free fraction
A
True
25
Cortisol-binding globulin is decreased in obesity which may result in increased amount of the endogenous and synthetic corticosteroid free fraction
True
26
Cortisol-binding globulin is increased by estrogen therapy which may reduce the endogenous and synthetic corticosteroid free fraction
True
27
Cortisol-binding globulin is increased by pregnancy which may reduce the endogenous and synthetic corticosteroid free fraction
True
28
Cortisol-binding globulin is increased by hyperthyroidism which may reduce the endogenous and synthetic corticosteroid free fraction
True
29
High dose corticosteroid therapy results in greater proportion of corticosteroid free fraction
True
30
Prolonged corticosteroid treatment increase the corticosteroid free fraction
True
31
All endogenous and synthetic corticosteroid are well distributed into Fetal tissue except prednisone (inactive form)
True
32
Gluconeogenesis is a glucocorticoid effect that generates glucose at the expense of amino acids derived from endogenous proteins (glucose metabolism)
True
33
The glucocorticoid effect of Corticosteroids produce peripheral insulin resistance which impedes glucose absorption by various body tissues (glucose metabolism)
True
34
The glucocorticoid effect of corticosteroids is to enhance glycogen storage in the liver (glucose metabolism)
True
35
The glucocorticoid effect of corticosteroids is to stimulate lipid stores to undergo lipolysis, thus generating increased amounts of triglycerides for which to derive energy (lipid metabolism)
True
36
The net glucocorticoid effect of corticosteroids is a catabolic state that produces carbohydrates at the expense of protein and fat stores
True
37
The glucocorticoid effect of corticosteroids is to redistribute fat to central locations resulting in lipodystrophy that's is characteristic for the body habitus in Cushing's syndrome (lipid metabolism)
True
38
Corticosteroids are metabolised in the liver and extrahepatic sites to form relatively water soluble metabolites which are then excreted in the kidneys
True
39
11 beta-hydroxysteroid dehydrogenase in the liver is necessary to covert cortisone to cortisol (hydrocortisone), and to convert prednisone to prednisolone
True (therefore only cortisol and prednisolone are biologically active here)
40
Severe liver disease may impair the conversion of cortisone to cortisol (hydrocortisone) and prednisone to prednisolone by 11 beta-hydroxysteroid dehydrogenase
True (therefore prednisolone is more appropriate in patients with liver disease than prednisone)
41
The administration of prednisolone rather than prednisone to patients with advanced liver disease is appropriate
True (as conversion of prednisone to prednisolone is mediated by 11 beta-hydroxysteroid dehydrogenase in the liver)
42
The plasma half lives of the various exogenous synthetic corticosteroids do not correlate well with the duration of biological activity I.e. Short, intermediate, long acting (potency)
True (a much more important measure of duration of activity is the duration of ACTH suppression after the administration of a single dose of corticosteroid)
43
The duration of activity of corticosteroids correlate well with glucocorticoid and anti-inflammatory effects (potency)
True
44
There is an inverse correlation between the duration of action and the relative mineralocorticoid effects of corticosteroids
True (long acting dexamethasone and betamethasone don't have mineralocorticoid activity, in contrast to short acting cortisone and cortisol/hydrocortisone)
45
Prednisone and prednisolone (intermediate acting corticosteroid) have mild mineralocorticoid activity
True (in contrast to the other intermediate acting corticosteroid methylprednisolone and Triamcinolone which do not exhibit mineralocorticoid activity)
46
The hypothalamus secretes CRF (corticotropin-releasing factor) which stimulates the anterior pituitary gland to produce ACTH
True
47
The anterior pituitary gland secretes ACTH (adrenocorticotrophic hormone) which stimulates the zona fasciculata of the adrenal cortex to produce and release cortisol
True
48
ACTH from the anterior pituitary gland also stimulates adrenal androgen synthesis
True
49
ACTH from the anterior pituitary gland is not involved in stimulating the release of the mineralocorticoid aldosterone from the adrenal glands
True
50
The basal production of cortisol of 20-30mg daily is equivalent to 5-7.5mg of prednisone daily
True
51
The maximal stress production of cortisol of 300mg daily is equivalent to 75mg daily of prednisone
True
52
The minor stress production of cortisol is about 2-3 times the basal production of 20-30mg daily
True
53
The hypothalamus is the first to be suppressed and the first to recover full function in response to exogenous corticosteroids and stress
True (therefore the hypothalamus is the most important part of the HPA-axis in terms of stress responsiveness)
54
The adrenal gland is the slower to be suppressed and much slower to recover full function in response to exogenous corticosteroids and stress
True
55
CRF from the hypothalamus (and hence ACTH from the anterior pituitary gland) have innate diurnal variations tied to sleep cycle with the highest production in mid-sleep and the lowest production in late afternoon
True
56
Increased cortisol levels reduce CRF and ACTH production
True
57
In response to stress, there is increased CRF release from the hypothalamus and subsequently increased ACTH release from the anterior pituitary
True
58
The hypothalamo-pituitary-adrenal axis serves to maintain glucose homeostasis
True
59
Corticosteroids play a role in maintaining adequate glucose levels for brain function
True
60
ACTH has no role in endogenous mineralocorticoid (aldosterone) production
True (the control is through the renin-angiotensin system and and serum potassium levels)
61
Aldosterone is the primary endogenous mineralocorticoid hormone
True
62
The primary effect of aldosterone is sodium reabsorption resulting in water reabsorption at the proximal tubule in the kidneys
True (as sodium is exchanged for potassium, an excessive mineralocorticoid effect leads to hypokalaemia)
63
Corticosteroid with significant mineralocorticoid effects I.e. Hydrocortisone have a similar effect on sodium, potassium, and fluid balance as aldosterone
True
64
Potassium is exchanged for sodium at the proximal tubules of the kidneys as a result of mineralocorticoid effects of aldosterone, and excessive mineralocorticoid effect may lead to hypokalaemia
True
65
Aldosterone production and regulation is via the renin-angiotensin system
True
66
The major priority for mineralocorticoids is to maintain sodium and fluid homeostasis, including normal blood pressure
True
67
There is only 1 glucocorticoid receptor (located in the cytoplasm) which accounts for the endogenous glucocorticoid effects as well as the pharmacological effects of synthetic corticosteroids
True
68
There are rare cases of hereditary glucocorticoid resistance, in which there are mutations in the glucocorticoid receptor (GCR) gene
True (although there are also cases of relative resistance which lack mutations or polymorphisms in the GCR gene)
69
Relative resistance to corticosteroids is due to altered corticosteroid bioavailability, altered ligand binding to the cytosolic glucocorticoid receptor (GCR), or altered translocation of the activated GCR complex to the nucleus and could represent a negative feedback system, with downregulation of the GCR after prolonged or high dose corticosteroid therapy
True
70
The 2 well described transcription factors with a central role in the amplification on the inflammatory response as a result of corticosteroids are nuclear factor kappa B (NFkB) and Activating Protein-1 (AP-1)
True (there is tremendous overlap with the inflammatory response genes induced by NFkB and AP-1)
71
Nuclear factor kappa B (NFkB) is biologically inactive as long as it is bound to inhibitor kappa B (IkB), and NFkB is activated when any biological stimuli degrades IkB, thus freeing NFkB to be a biologically active transcription factor
True (coricosteroids increase production of IkB, therefore resulting in reduced free NFkB)
72
Corticosteroids reduces the effects of Nuclear factor kappa B (NFkB) in 2 ways - (1) increase the production of Inhibitor kappa B (IkB), resulting in more NFkB being bound to IkB leading to decreased free NFkB
(2) directly bind to free NFkB and thereby inhibiting the transcription factor
True
73
Corticosteroids can directly induce apoptosis in lymphocytes and eosinophils
True (this could explain the effect of corticosteroid in autoimmune disorders, allergic disorders, and neoplastic disorders)
74
The effect of corticosteroids in inducing apoptosis in lymphocytes and eosinophils may be an a underlying explanation for corticosteroid effects in autoimmune disorders (apoptosis of auto-reactive T cells), allergic disorders (apoptosis of eosinophils), and certain neoplastic disorders (apoptosis of malignancy T cells)
True
75
Systemic fungal infections is an absolute contraindication for systemic corticosteroid therapy
True
76
Herpes simplex keratitis is an absolute contraindication for systemic corticosteroid therapy
True
77
Hypertension is a relative contraindication for systemic corticosteroid therapy
True (mineralocorticoid effect of sodium retention and glucocorticoid induced vasoconstriction worsens hypertension)
78
Congestive cardiac failure is a relative contraindication for systemic corticosteroid therapy
True (mineralocorticoid effect of sodium reabsorption and water reabsorption causing fluid overload)
79
Prior psychosis is a relative contraindication for systemic corticosteroid therapy
True (corticosteroids possibly precipitate this due to electrolyte shifts, altered nerve excitability, mild cerebral oedema from sodium and water retention)
80
Severe depression is a relative contraindication for systemic corticosteroid therapy
True
81
Active peptic ulcer disease is a relative contraindication for systemic corticosteroid therapy
True (corticosteroid may cause reduced mucus production and increased acid secretion)
82
Recent bowel anastomosis is a relative contraindication for systemic corticosteroid therapy
True (glucocorticoid catabolic effects producing decreased wound healing)
83
Active TB is a relative contraindication for systemic corticosteroid therapy
True (immunosuppressive effect of corticosteroids)
84
A positive tuberculin skin test is a relative contraindication for systemic corticosteroid therapy
True (immunosuppressive effect of corticosteroid and TB reactivation)
85
Diabetes is a relative contraindication for systemic corticosteroid therapy
True (corticosteroid effect on glucose metabolism resulting in hyperglycaemia)
86
Osteoporosis is a relative contraindication for systemic corticosteroid therapy
True (corticosteroid effect on bone metabolism resulting in increased osteoclasts activity, decreased osteoblast activity, decreased GI absorption of calcium, increased renal excretion of calcium - secondary hyperparathyroidism and bone resorption)
87
Cataracts is a relative contraindication for systemic corticosteroid therapy
True (corticosteroids cause altered lens proteins)
88
Glaucoma is a relative contraindication for systemic corticosteroid therapy
True
89
Pregnancy is a relative contraindication for systemic corticosteroid therapy
True
90
Systemic Corticosteroids can cause hyperlipidaemia due to lipolysis and fat redistribution
True
91
Systemic corticosteroids cause Cushingoid changes due to altered fat distribution from overall fat catabolism
True
92
Systemic corticosteroids may case growth impairment due to reduced growth hormone production resulting in delays skeletal maturation
True
93
Systemic corticosteroids may cause myopathy due to reduced glucose and amino acid uptake by muscle cells, leading to muscle atrophy and wasting
True
94
Systemic corticosteroids have a greater effect on T cells than B cells
True (B cell effects are more evident with higher doses of corticosteroids)
95
Systemic corticosteroids inhibit granulation of mast cells, resulting in decreased histamine release
True
96
Systemic corticosteroids reduce angiogenesis in wound healing and in proliferative lesions I.e. Haemangiomas
True
97
Systemic corticosteroids causes vasoconstriction
True
98
Brief bursts of systemic corticosteroids for 2-3 weeks is surprisingly safe and useful in self-limiting dermatoses
True
99
Lower dose long term systemic corticosteroid regimens at or very near replacement/physiologic levels of corticosteroid are reasonably safe
True
100
There is an increased risk for more serious complications with supraphysiologic/pharmacologic corticosteroid doses longer than 3-4 weeks
True
101
Systemic corticosteroids adverse effects on the HPA axis include steroid withdrawal syndrome and addisonian crisis
True
102
Systemic corticosteroids glucocorticoid adverse effects include hyperglycaemia and increased appetite/weight gain
True
103
Systemic corticosteroids mineralocorticoid adverse effects include hypertension, CCF, excessive weight gain and hypokalaemia
True (due to sodium retention and potassium loss)
104
Systemic corticosteroids lipid adverse effects include hypertriglyceridaemia, Cushingoid changes, and menstrual irregularity (decreased gonadotropin levels I.e. LH and FSH from the ovaries)
True (lipolysis and altered fat deposition = lipodystrophy)
105
Systemic corticosteroids bone adverse effects include osteoporosis, osteonecrosis, and hypocalcaemia (indirect)
True
106
Systemic corticosteroids GI adverse effects include peptic ulcer disease, bowel perforation, fatty liver, oesophageal reflux, nausea and vomiting
True
107
Systemic corticosteroids ocular adverse effects include cataracts, glaucoma, infections, and refraction changes (from hyperglycaemia)
True
108
Systemic corticosteroids psychiatric adverse effects include psychosis, agitation or personality change, depression (from prednisone phobia or dependency)
True
109
Systemic corticosteroids neurological adverse effects include pseudotumour cerebri, epidural lipomatosis and peripheral neuropathy (? from hyperglycaemia)
True (interestingly pseudotumour cerebri is also an adverse effect of retinoids, and both glucocorticoid and retinoid receptors are part of the same receptor family)
110
Systemic corticosteroids infectious adverse effects include TB reactivation and opportunistic infections (I.e. Deep fungi), and prolonged herpes virus infections
True
111
IV methylprednisolone pulse therapy may cause electrolyte shifts leading to cardiac dysrhythmias and seizures
True
112
IV methylprednisolone pulse therapy may cause cardiac dysrhythmias (from the electrolyte shifts) and cardiac monitoring is recommended
True
113
IV methylprednisolone pulse therapy may cause seizures (from the electrolyte shifts)
True
114
Systemic corticosteroids may result in opportunistic malignancies
True
115
Prednisone bursts commonly cause increased appetite and weight gain
True
116
Prednisone bursts commonly cause fluid retention with oedema and possibly weight gain
True
117
Prednisone bursts commonly cause patients to be wired or weird
True
118
Prednisone bursts commonly cause some patients to be be depressed during the tapering phase
True
119
Prednisone bursts commonly cause mild GI symptoms
True
120
Systemic corticosteroids may affect wound healing and result in non-healing wounds, ulcers, striae, atrophy and telengiectasia
True (from decreased collagen/ground substance/re-epithelialisation/angiogenesis)
121
Systemic corticosteroids may affect the pilosebaceous unit and result in steroid acne and steroid Rosacea
True ( prom pityrosporum ovale and androgenecity)
122
Systemic corticosteroids may affect the vascular system and result in purpura
True (due to catabolic effects on vascular smooth muscle)
123
Systemic corticosteroids may affect the susceptibility for cutaneous infections and result in staphylococcal and herpes virus infections
True
124
Systemic corticosteroids may affect hair growth and result in telogen effluvium and hirsutism
True (androgenic effects causing hirsutism, uncertain mechanism for telogen effluvium)
125
Systemic corticosteroids may cause flare of pustular psoriasis and rebound of poison ivy/oak contact dermatitis
True
126
Systemic corticosteroids may cause acanthosis nigricans
True (due to causing insulin resistance)
127
Injectable corticosteroids may result in fat atrophy and crystallisation of injectable material
True (due to lipolysis of subcutaneous fat)
128
Greater HPA axis suppression is observed with shorter intervals of low dose IM corticosteroid administration rather than with longer intervals of high dose treatment
True (low dose IM steroid at 2-4 week intervals produced greater suppression that's higher doses at 6 week intervals)
129
Oral corticosteroid is preferred over IM corticosteroid due to the precision of dosing and active patient participation
True (only exception would be in various subsets of hand dermatoses where there is thick stratum corneum on the palms and the general challenge of successfully treating this topically, long acting IM Triamcinolone I.e. Kenalog may be considered for 2-3 times a year)
130
IM corticosteroids may cause cold abscess at the injection site
True
131
IM corticosteroids may cause subcutaneous fat atrophy at the injection site
True
132
IM corticosteroids may cause crystal deposition at the injection site
True
133
Oral and IM corticosteroids may cause menstrual irregularities due to decreased gonadotropin levels
True (traditionally, menstrual abnormalities were thought to be due to IM corticosteroids only)
134
IM corticosteroids may cause increased incidence of purpura as compared to oral regimens
True
135
Sudden death of presumed cardiac origin is a notable complication of Pulse IV methylprednisolone, although the vast majority of cardiac complications have occurred outside of dermatologic settings
True (acute electrolyte shifts have been postulated)
136
Careful potassium infusions may minimise the risk of potentially serious cardiac adverse effects from pulse IV methylprednisolone therapy
True (acute electrolyte shifts postulated)
137
Pulse IV methylprednisolone may potentially cause life threatening anaphylaxis
True
138
The suppression of lymphocyte subsets is greater with pulse IV methylprednisolone therapy than with standard doses of oral corticosteroid therapy, with corticosteroid induced apoptosis likely to play a key role in this effect
True
139
The abrupt cessation of corticosteroid in patients undergoing major stressors I.e. Major surgery, trauma, illness, severe gastroenteritis with fluid and electrolyte loss may precipitate an adrenal crisis
True
140
High systemic corticosteroid dose in patients with a family/personal history of diabetes, obesity may precipitate hyperglycaemia
True
141
Administration of systemic corticosteroid with high mineralocorticoid effect (fludrocortisone, hydrocortisone, prednisone, prednisolone), prolonged therapy for over 1 year and pulse IV corticosteroid therapy in patients with a prior history of hypertension/elderly patients may precipitate hypertension
True
142
Administration of a systemic corticosteroid with high mineralocorticoid effect in patients with prior well or partially compensated CCF may precipitate CCF
True
143
High dose systemic corticosteroids in patients with a personal/family history of hyperlipidaemia, diabetes, hypothyroidism or high fat calorific intake may precipitate hyperlipidaemia
True
144
Systemic corticosteroid therapy for at least 2-3 months in patients with excessive calorific intake due to increased appetite may precipitate Cushingoid changes
True
145
Chronic pharmacologic dose systemic corticosteroids therapy in children with organ transplant or autoimmune condition requiring indefinite corticosteroid therapy may cause growth impairment
True (although catch up growth is possible when corticosteroids are reduced to physiologic levels or below)
146
Systemic corticosteroid therapy in female patients who are elderly, thin, inactive may precipitate osteoporosis
True (men at risk as well)
147
Continuous pharmacologic corticosteroid therapy for at least 2-3 months in patient with signifying trauma, smoking, alcohol abuse hypercoagulable conditions and hyperlipidaemia are at increased risk of osteonecrosis
True
148
Dose and duration of corticosteroid therapy is not a key determinant of risk of bowel perforation
True (recent bowel anastomosis and active diverticulitis are main risks)
149
Total corticosteroid dose of 1g in patients on concomitant aspirin, NSAID therapy, history of peptic ulcer disease or autoimmune connective tissue disease are at increased risk of peptic ulcer disease
True
150
Corticosteroid dose of at least 40mg/day and particularly at doses above 80mg/day in patients with a family history of psychosis, baseline high anxiety and female gender are at increased risk for agitation and psychosis
True
151
Prolonged high corticosteroid dose in patients on multi drug immunosuppression therapy and organ transplant patients are at risk of opportunistic infections
True
152
Fluorinated corticosteroids and rapid tapering of corticosteroids in patients with lack of exercise are at risk of myopathy
Tru
153
Sodium restriction and using a corticosteroid with low mineralocorticoid effect can prevent corticosteroid-induced hypertension
True (monitor blood pressure)
154
Low calorie and low saturated fat diet can prevent corticosteroid-induced hyperlipidaemia
True (may need statins or gemfibrozil to treat resulting hyperlipidaemia)
155
Calcium and vitamin D can prevent corticosteroid-induced osteoporosis
True (consider serial DEXA scans for monitoring, and bisphosphonates may be required to treat if result in osteoporosis)
156
Avoidance of trauma/alcohol excess/smoking can prevent corticosteroid-induced osteonecrosis
True
157
Caution with administration of corticosteroids after bowel surgery can prevent corticosteroid-induced bowel perforation
True
158
Administration of H2 antihistamines in higher risk patients can prevent corticosteroid-induced peptic ulcer disease
True (history and consider upper GI endoscopy)
159
Sunglasses may help prevent corticosteroid-induced cataracts
True (consider slit lamp exam every 6-12 months)
160
Doxepin (if agitation present) and possible antipsychotics may be needed to managed corticosteroid-induced psychosis
True
161
Exercise and caution with corticosteroid tapering after high dose therapy can prevent corticosteroid-induced myopathy
True
162
Significant corticosteroid-induced hyperlipidaemia increases the risk of pancreatitis
True
163
Adrenal crisis is a potentially fatal corticosteroid complication that can be avoided through aggressive emergency room or postoperative preventative and therapeutic measures
True (this complication is distinctively uncommon in the current era due to heightened awareness)
164
Bowel perforation is a potentially fatal preventable corticosteroid complication where tremendous caution is needed with the use of systemic corticosteroid after recent bowel anastomosis and with active diverticulitis
True
165
Peptic ulcer perforation (gastric ulcer more common than duodenal ulcer) is a potentially fatal corticosteroid complication most likely to occur in patients with adjunctive NSAID drugs and history of peptic ulcer disease
True (albeit controversial, proactive use of H2 antagonist or PPI for patients with prior history of peptic ulcer disease and for patients with symptoms even possibly related to peptic ulcer disease is suggested)
166
Pancreatitis is a potentially fatal corticosteroid complication resulting from severe triglyceride elevations and the possible role of increased viscosity of pancreatic secretions leasing to obstruction
True (any reports of severe abdominal pain must be intervened promptly)
167
Severe hyperglycaemia (diabetic ketoacidosis) is a potentially fatal corticosteroid complication most likely to occur with pre-existing diabetes mellitus
True (the widespread availability of home glucose monitoring has made this a rare complication)
168
Opportunistic infections is a potentially fatal corticosteroid complication more likely in patients with multidrug immunosuppressive regimens common with organ transplantation
True
169
Immunosuppression carcinogenesis/opportunistic malignancies predominantly from viral induced malignancies (Kaposi's sarcoma, non-Hodgkins lymphoma, SCC) is a potentially fatal corticosteroid complication in patients on immunosuppression regimen in organ transplantation setting
True (although Kaposi's sarcoma may be associated with corticosteroid use alone without HHV-8 aetiology)
170
Multiple studies in humans concerning patients with corticosteroid-dependent systemic conditions during pregnancy have demonstrated no significantly increased risk of congenital malformations in humans I.e. Not teratogenic
True (although systemic corticosteroids should be used only when the drug is clearly indicated and if the potential benefits far exceed the potential risk to the mother and fetus)
171
Fetal HPA-axis suppression is important to consider when systemic corticosteroid therapy is used near the time of delivery as there may an increased risk of stillbirth and spontaneous abortion
True
172
Secondary exogenous adrenal insufficiency due to prolonged high dose corticosteroid therapy for at least 3-4 weeks results in no significant mineralocorticoid abnormalities (normal), no increased ACTH production (normal) and no pituitary tropic hormone abnormalities (normal)
True (significant mineralocorticoid reduction with resultant fluid and electrolyte abnormalities and increased ACTH production with resultant hyperpigmentation from stimulatory effect on melanocytes are noted only in primary adrenal insufficiency I.e. Addison's disease)
173
Corticosteroid doses exceeding physiologic levels for at least 3-4 weeks can produce clinically relevant mild HPA-axis suppression
True
174
Divided dose regimens and single dose therapy given at a time other than the morning will increase the risk of HPA-axis suppression
True
175
The longer acting corticosteroid preparations are more likely to produce HPA-axis suppression than are short and intermediate duration corticosteroid
True
176
Even though alternate day corticosteroid therapy lessens the risk of HPA-axis suppression, it does not speed the recovery once this suppression occurs
True
177
The direct corticosteroid effect in producing elevated blood glucose is much slower than the catecholamine response and both ACTH and cortisol can indirectly induce rapid glucose elevation through release of epinephrine/adrenaline
True
178
The primary test of basal HPA-axis function is the morning cortisol level and this tests the function of the adrenal gland
True (peak level is at 8am and the trough level is late afternoon) - generally recommended to omit the morning corticosteroid dose on the day the cortisol level is checked
179
With prolonged corticosteroid therapy, cortisol levels <10 mg/dL suggest impaired basal HPA-axis function
True
180
The ACTH stimulation test is a provocative test of the function of the adrenal gland under stress, and not a test of the function of the entire HPA-axis
True
181
In Steroid withdrawal syndrome there is no change in the serum cortisol level, although it has been postulated that there may be a sudden decrease in corticosteroid available at the cellular level
True
182
Steroid withdrawal syndrome is precipitated by abrupt corticosteroid tapering with intermediate and chronic duration therapy
True (at pharmacologic doses beyond 2-3 weeks it is possible to develop steroid withdrawal syndrome) - the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms
183
Mild to moderate steroid withdrawal syndrome is characterised by fatigue and lethargy
True (the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms)
184
Mild to moderate steroid withdrawal syndrome is characterised by mood swings
True (the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms)
185
Mild to moderate steroid withdrawal syndrome is characterised by headache
True (the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms)
186
Mild to moderate steroid withdrawal syndrome is characterised by arthralgias and myalgias
True (the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms)
187
Severe steroid withdrawal syndrome is characterised by the GI symptoms anorexia, nausea and vomiting
True (the return to higher corticosteroid doses with more gradual subsequent corticosteroid tapering will typically eliminate the symptoms)
188
A systematic review noted that there was no perioperative haemodynamic compromise in the absence of corticosteroid stress doses in patients who have been on prolonged pharmacologic doses of corticosteroid therapy
True (therefore in the absence of primary/adrenal or secondary/hypothalamus or pituitary insufficiency, patients simply need to take their daily current maintenance dose of corticosteroid I.e. Physiologic doses would suffice) - this has challenged the traditional approach of supplementing higher doses during stress
189
The majority of potentially serious drug interactions involving systemic corticosteroids are due to dexamethasone and methylprednisolone
True (few involve prednisone or prednisolone)
190
Azole antifungal agents I.e. Ketoconazole may increase the levels and potential toxicity of various corticosteroids as it is a potent CYP3A4 inhibitor
True (metabolism of corticosteroids generally take place in the liver)
191
Macrolide antibacterial agents I.e. Erythromycin > clarithromycin may increase the levels and potential toxicity of various corticosteroids as it is a potent CYP3A4 inhibitor
True (metabolism of corticosteroids generally take place in the liver)
192
Sex steroids I.e. Estrogens and oral contraceptives may increase the half life and decrease the clearance of various corticosteroids
True (thus increasing the potential toxicity of corticosteroids)
193
Anticonvulsants I.e. Phenytoin and phenobarbital may decrease the levels and activity of various corticosteroids as it is a CYP3A4 inducer
True (metabolism of corticosteroids generally take place in the liver)
194
Anti-tuberculous therapy I.e. Rifampin may decrease the levels and activity of various corticosteroids as it is a CYP3A4 inducer
True (metabolism of corticosteroids generally take place in the liver)
195
Aminoglutethimide may reduce the serum level and activity of various corticosteroids due to dexamethasone-induced adrenal suppression
True
196
Cholestyramine may decrease the levels of hydrocortisone
True
197
Ephedrine may decrease the half life and increase the clearance of dexamethasone
True
198
Systemic corticosteroids may increase the serum levels and potential toxicity of diuretics (potassium-depleting ones) as the hypokalaemia potential of the diuretics may be aggravated by corticosteroid potassium loss
True (particularly in corticosteroids with mineralocorticoid activity)
199
Systemic corticosteroids (primarily methylprednisolone) may increase the serum levels and potential toxicity of immunosuppressants I.e. Cyclosporine (similar to corticosteroids, CsA is also a substrate of CYP3A4)
True (cyclosporine in combination with corticosteroid is standard in transplantation and for autoimmune disorders)
200
Systemic corticosteroids may increase the serum levels and potential toxicity of inotropic agents I.e. Digitalis glycosides due to corticosteroid-induced potassium loss
True (particularly for corticosteroids with mineralocorticoid activity)
201
Corticosteroids may induce a state of insulin resistance, thereby reducing the efficacy of insulin and resulting in increased blood glucose
True
202
Corticosteroids may reduce the serum levels and efficacy of salicylates
True
203
Corticosteroids may reduce the serum levels of isoniazid antituberculous therapy
True
204
Corticosteroids may increase or decrease warfarin anticoagulant activity
True (unpredictable effect)
205
Concomitant usage of Corticosteroids and xanthine bronchodilators may result in alterations in either theophylline or corticosteroid activity
True
206
When anticipating long term corticosteroid therapy, consider baseline screening blood pressure, weight and ophthalmoscopic examination for cataracts
True (risk of hypertension, weight gain and cataracts)
207
When anticipating long term corticosteroid therapy, strongly consider baseline TB screening using the tuberculin skin test and chest X-Ray
True (risk of opportunistic infections I.e. tab and reactivation of latent TB)
208
When anticipating long term corticosteroid therapy, consider baseline fasting glucose level and triglycerides as well as potassium level
True (risk of hyperglycaemia, hyperlipidaemia and hypokalaemia)
209
During follow up of patients on long term corticosteroid therapy above physiologic/at pharmacologic doses, perform blood pressure and weight and a thorough history for adverse effects at 1 month and then every 2-3 months
True
210
During follow up of patients on long term corticosteroid therapy above physiologic/at pharmacologic doses, consider ophthalmology examination for cataracts and glaucoma every 6 to 12 months
True (6 months initially and at least 12 months long-term)
211
During follow up of patients on long term corticosteroid therapy above physiologic/at pharmacologic doses, monitor fasting glucose, fasting triglycerides and potassium levels at 1 month and then every 3-4 months
True
212
Near the time of cessation of long term pharmacologic dose corticosteroid therapy, consider the morning cortisol level to assess basal adrenal function or a test of the entire HPA-axis
True (optional, and most clinical scenarios in dermatology do not require his morning cortisol testing)
213
Consider cardiac monitoring during pulse IV methylprednisolone therapy
True (risk of fatal cardiac dysrhythmias due to electrolyte shifts)
214
Consider daily electrolyte and glucose levels during pulse IV methylprednisolone therapy
True
215
Seek to attain physiologic or alternate-day doses of corticosteroid therapy within 1-2 months, if this is not possible (or unlikely to be possible) then use 'steroid-sparing therapy'
True
216
To maximise the safety of systemic corticosteroids, use "attack" (quickly control the disease process), then reasonably quickly "retreat" (taper corticosteroid) philosophy
True
217
In the presence of a relative contraindication for systemic corticosteroid therapy, medical management of this relative contraindication may allow careful corticosteroid therapy
True
218
The careful clinician will anticipate risk factors and relative contraindications associated with systemic corticosteroid therapy
True
219
The careful clinician will prevent adverse effects associated with systemic corticosteroid therapy by being proactive and take preventative measures
True (I.e. H2 antagonists or PPI for patients at risk of peptic ulcer disease)
220
The careful clinician will diagnose the adverse effects associated with systemic corticosteroid therapy early by monitoring labs, encouraging home monitoring and educating patients and increasing their awareness about the potential adverse effects
True
221
The careful clinician will manage adverse effects associated with systemic corticosteroid therapy
True
222
Corticosteroid therapy given as a single oral dose in the morning with an intermediate-duration corticosteroid such as prednisone most closely approximates the body's own diurnal variation of cortisol production
True (divided doses, typically given twice daily are reserved for acute therapy for severe potentially life threatening illnesses such as Pemphigus vulgaris)
223
Divided doses of systemic corticosteroids, typically given twice daily are reserved for acute therapy for severe potentially life threatening illnesses such as Pemphigus vulgaris
True
224
When a constant total daily dose is given, divided-dose regimens have greater therapeutic benefits than equivalent daily-dose regimens
True (although divided-dose regimens produce a greater risk of adverse effects than a comparable dose given as a single daily-dose)
225
Divided-dose corticosteroid regimens produce a greater risk of adverse effects than a comparable dose given as a single daily-dose
True (although divided-dose regimens have greater therapeutic benefits)
226
The briefer the duration for which corticosteroid therapy exceeds physiologic doses, the lower the risk of significant adverse effects
True
227
Brief bursts of corticosteroid therapy are 2-3 weeks or less
True
228
Intermediate-duration corticosteroid therapy is over 3-4 weeks and up to 3-4 months at the most
True
229
Physiologic/replacement corticosteroid therapy is 5-7.5mg daily of prednisone or its equivalent
True
230
Pharmacologic dosage ranges at the initiation of therapy include high dose (>60mg daily prednisone), moderate dose (40-60mg daily prednisone) and low dose (<40mg daily prednisone)
True (apart from potentially life threatening dermatoses such as Pemphigus vulgaris and bullous pemphigoid, most dermatologic conditions can be controlled by moderate to low dosage regimens)
231
Prednisone is generally the systemic corticosteroid of choice for most dermatoses
True (the prednisone duration of action is optimal for allowing daily or alternate-day therapy)
232
In Europe, prednisolone is commonly used instead of prednisone
True
233
Prednisolone (1) requires no metabolic conversion to be active; (2) has a quicker onset of action; (3) has a cortisol-binding globulin affinity greater than that of prednisone
True (drawbacks to prednisolone use is its greater cost and smaller number of dosage options I.e. Only in 5mg tablets and liquid formulations)
234
Overall, the mineralocorticoid effect and duration of action are much more important factors in the choice of corticosteroid therapy than is the anti-inflammatory potency of the product
True (as various preparations have equivalent anti-inflammatory efficacy at therapeutically equivalent doses)
235
Prednisone and prednisolone share a reasonable profile of mineralocorticoid effect and duration of action compared to other short acting alternatives
True
236
The mineralocorticoid effect of hydrocortisone is excessive (should the potential for sodium and fluid retention be deleterious to a specific patient) and may not allow for steady state day-long control of disease activity
True
237
The prednisone dose should be increased to the last effective dose level if a significant disease flare occurs during the tapering process
True
238
The risk of cataracts, osteoporosis and possibly osteonecrosis are not reduced by alternate-day corticosteroid therapy
True
239
The type I Isoform of 11 beta-hydroxysteroid dehydrogenase catalyses conversion of endogenous cortisone (inactive) to cortisol (active), and converts exogenous prednisone (inactive) to prednisolone (active), whereas the type II Isoform of the same enzyme reverses this conversion and reverting the active forms back to the inactive forms
True (dexamethasone and betamethasone are active independently of this enzyme)
240
Night time dosing of corticosteroid tends to produce greater HPA-axis suppression
True
241
Cortisol (hydrocortisone) and cortisone have the greatest mineralocorticoid activity
True
242
Dexamethasone, betamethasone and methylprednisolone have the least mineralocorticoid activity
True
243
Prednisone and prednisolone have intermediate mineralocorticoid activity
True
244
Hypertension from corticosteroid has recently been found to be largely independent of their naturetic effect, and is probably more related to vasoconstriction and increased myocardial contractility (duration of effect and thus HPA-axis suppression)
True (the long acting betamethasone and dexamethasone produce a much greater risk of HPA-axis suppression than intermediate acting prednisone, prednisolone and methylprednisolone)
245
The relative risk of TB for prednisone doses of at least 15mg daily are 8 times higher than doses < 15mg daily
True
